Broad Coverage or Concentrated Bets? Analyzing the Differences Between Healthcare Funds VHT and XPH

Life Science

Viking Therapeutics Aims High at $92 Target, But Clinical Risks Remain

Life Science

UNH’s TPG Deal: Can It Reignite a Stalled Valuation Recovery?

Life Science

From $275 to $461, UnitedHealth Regains Confidence Through a Turnaround Script

Life Science

Goldman Sachs Adds Vertex to Conviction List With $653 Target

Life Science

AbbVie’s Diversification Bet Gradually Shows Results, While Pfizer Seeks a Second Takeoff Through Its GLP-1 and Oncology Pipelines

Life Science

Moderna’s 5x Surge Just Hit a Wall. Time to Buy or Bail?

Life Science

Pfizer Trades Below 10x P/E, But Does That Signal a Value Trap or a Long-Term Opportunity?

Life Science

Analysts See Triple Upside in Viking Therapeutics Amid High Stakes

Life Science

Moderna Already Won Round One—or Is BioNTech the Smarter Bet?

Life Science

Eli Lilly Swallows Merida, Expanding Pipeline with Another Strategic Acquisition

Life Science

Gene-Editing Pioneer CRISPR Therapeutics Worth a Bet Before Year-End? Two Catalysts Await Release

Life Science

Intuitive Surgical Stock Crashes 30%, But Wall Street Isn’t Flinching

Life Science

GLP-1 Concept Stock Amylyx Soars 247% Year-to-Date: How Much Room Remains for Upside?

Life Science

Medtronic Beats Estimates, Raises Full-Year Guidance; Is a Valuation Recovery Underway?

Life Science